📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Aarey Drugs & Pharmaceuticals Approves Q3 FY26 Unaudited Financial Results
Aarey Drugs & Pharmaceuticals Limited held a board meeting on February 11, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board confirmed the submission of the Limited Review Report and MD/CFO certifications as per SEBI regulations. The company operates in a single business segment, focusing on bulk drugs and chemical imports. While the specific profit and loss figures were not detailed in this cover letter, the results have been officially taken on record.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025.
The board meeting was held on February 11, 2026, from 3:00 p.m. to 6:30 p.m.
MD and CFO provided formal certification regarding the accuracy of the financial statements.
The company confirmed it operates within a single reporting segment.
💼 Action for Investors
Investors should look for the detailed financial tables on the stock exchange to evaluate revenue growth and margin performance. Monitor the company's ability to manage raw material costs in the bulk drug and solvent import business.